Health and Healthcare
Affimed Sinks Despite Positive Interim Results
Published:
Last Updated:
Affimed N.V. (NASDAQ: AFMD) shares dropped sharply early on Friday after the company released new results from its early stage trial with Keytruda. Affimed presented new interim data from the Phase 1b dose escalation study evaluating AFM13, its lead NK cell engager candidate, at the European Hematology Association (EHA) 23rd Congress in Stockholm, Sweden
Ultimately, the assessment of 18 patients treated at the highest AFM13 dose showed best overall response rate (ORR) of 89% and complete metabolic response rate (CmR) of 28%. The ORR and CmR for these 18 patients compare favorably with those of anti-PD-1 monotherapy in similar patient populations.
Responders included three patients who were either primary refractory to or had relapsed during front-line therapy and were refractory to all subsequent lines of therapy.
The combination of AFM13 and pembrolizumab was well tolerated, with most adverse events mild to moderate in nature and manageable with standard of care measures.
Dr. Stephen Ansell, principal investigator of the study, commented:
The high response rates in this study, in terms of both partial and complete responses, continue to compare favorably to the historical data of anti-PD-1 monotherapy, and would be expected to translate into meaningful progression free and overall survival over time. Importantly, these data have shown that AFM13 can be safely administered in combination with Keytruda® and has the potential to improve patient outcomes.
Shares of Affimed closed Thursday at $2.45, with a consensus analyst price target of $7.43 and a 52-week range of $1.15 to $2.85. The shares were down 15% to $2.07 Friday morning.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
